Cargando…

Lipidomics in non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disorder in Western countries, comprises steatosis to nonalcoholic steatohepatitis (NASH), with the latter having the potential to progress to cirrhosis. The transition from isolated steatosis to NASH is still poorly understood...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kartsoli, Sofia, Kostara, Christina E, Tsimihodimos, Vasilis, Bairaktari, Eleni T, Christodoulou, Dimitrios K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475773/ https://www.ncbi.nlm.nih.gov/pubmed/32952872 http://dx.doi.org/10.4254/wjh.v12.i8.436

Ejemplares similares

Progressive, Qualitative, and Quantitative Alterations in HDL Lipidome from Healthy Subjects to Patients with Prediabetes and Type 2 Diabetes
por: Kostara, Christina E., et al.
Publicado: (2022)

Early Signs of Atherogenic Features in the HDL Lipidomes of Normolipidemic Patients Newly Diagnosed with Type 2 Diabetes
por: Kostara, Christina E., et al.
Publicado: (2020)

Effect of Clinical and Laboratory Parameters on HDL Particle Composition
por: Kostara, Christina E., et al.
Publicado: (2023)

A Study of the Metabolic Pathways Affected by Gestational Diabetes Mellitus: Comparison with Type 2 Diabetes
por: Spanou, Loukia, et al.
Publicado: (2022)

The Critical Role of the Branched Chain Amino Acids (BCAAs) Catabolism-Regulating Enzymes, Branched-Chain Aminotransferase (BCAT) and Branched-Chain α-Keto Acid Dehydrogenase (BCKD), in Human Pathophysiology
por: Dimou, Aikaterini, et al.
Publicado: (2022)

Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes
por: Bletsa, Evdoxia, et al.
Publicado: (2021)

Expanding the Molecular Disturbances of Lipoproteins in Cardiometabolic Diseases: Lessons from Lipidomics
por: Kostara, Christina E.
Publicado: (2023)

Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics
por: Riccio, Simona, et al.
Publicado: (2022)

Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
por: Huang, Jian, et al.
Publicado: (2023)

The Effect of Mycotoxins and Silymarin on Liver Lipidome of Mice with Non-Alcoholic Fatty Liver Disease
por: Bechynska, Kamila, et al.
Publicado: (2021)

Cancer surveillance in non-alcoholic fatty liver disease: A potential role for lipidomics
por: Best, Jan, et al.
Publicado: (2021)

Pathophysiology of Non Alcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2016)

LDL cholesterol estimation in patients with the metabolic syndrome
por: Gazi, Irene, et al.
Publicado: (2006)

Omics Analysis of Chemoresistant Triple Negative Breast Cancer Cells Reveals Novel Metabolic Vulnerabilities
por: Kordias, Dimitris, et al.
Publicado: (2022)

Lipidomic Analysis of the Protective Effects of Shenling Baizhu San on Non-Alcoholic Fatty Liver Disease in Rats
por: Deng, Yuanjun, et al.
Publicado: (2019)

The lipidome in nonalcoholic fatty liver disease: actionable targets
por: Pirola, Carlos J., et al.
Publicado: (2021)

Pathogenesis of non-alcoholic fatty liver disease
por: Dowman, J. K., et al.
Publicado: (2010)

Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease
por: Valenzuela-Vallejo, Laura, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease
por: Sattar, Naveed, et al.
Publicado: (2014)

Non-alcoholic fatty liver disease and liver secretome
por: Khan, Muhammad Sohaib, et al.
Publicado: (2022)

Alterations in circulating lipidomic profile in patients with type 2 diabetes with or without non-alcoholic fatty liver disease
por: Alfadda, Assim A., et al.
Publicado: (2023)

Nonalcoholic fatty liver disease stratification by liver lipidomics
por: Vvedenskaya, Olga, et al.
Publicado: (2021)

Mapping Proteome and Lipidome Changes in Early-Onset Non-Alcoholic Fatty Liver Disease Using Hepatic 3D Spheroids
por: Frandsen, Helle Sedighi, et al.
Publicado: (2022)

Lipidomics and Redox Lipidomics Indicate Early Stage Alcohol‐Induced Liver Damage
por: Koelmel, Jeremy P., et al.
Publicado: (2021)

Treatment of non-alcoholic fatty liver disease
por: Tolman, Keith G, et al.
Publicado: (2007)

Non-Alcoholic Fatty Liver Disease in Children
por: SINGER, CRISTINA, et al.
Publicado: (2014)

Iron and non-alcoholic fatty liver disease
por: Britton, Laurence J, et al.
Publicado: (2016)

Apoptosis and non-alcoholic fatty liver diseases
por: Kanda, Tatsuo, et al.
Publicado: (2018)

Pediatric Non-Alcoholic Fatty Liver Disease
por: Bush, Haley, et al.
Publicado: (2017)

Pathology of non-alcoholic fatty liver disease
por: Cataldo, Ivana, et al.
Publicado: (2021)

Non-Alcoholic Fatty Liver Disease in Children
por: Brecelj, Jernej, et al.
Publicado: (2021)

Metabolic drivers of non-alcoholic fatty liver disease
por: Bence, Kendra K., et al.
Publicado: (2020)

Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different
por: Malnick, Stephen D. H., et al.
Publicado: (2022)

Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
por: Ramai, Daryl, et al.
Publicado: (2021)

Hepatic Lipidomics and Molecular Imaging in a Murine Non-Alcoholic Fatty Liver Disease Model: Insights into Molecular Mechanisms
por: Rodríguez-Calvo, Ricardo, et al.
Publicado: (2020)

Integrative lipidomic and transcriptomic study unravels the therapeutic effects of saikosaponins A and D on non-alcoholic fatty liver disease
por: Li, Xiaojiaoyang, et al.
Publicado: (2021)

Autophagy and Non-Alcoholic Fatty Liver Disease
por: Lavallard, Vanessa J., et al.
Publicado: (2014)

Pediatric Non-Alcoholic Fatty Liver Disease
por: Delvin, Edgard, et al.
Publicado: (2015)

Non-alcoholic fatty liver disease and lipotoxicity
por: Wasilewska, Natalia, et al.
Publicado: (2021)

Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
por: Singh, Sukhpreet, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2uavanomsg3qmgd93piqc9i2t8